Results 81 to 90 of about 63,898 (235)
THE METABOLISM OF THALIDOMIDE: THE FATE OF THALIDOMIDE AND SOME OF ITS HYDROLYSIS PRODUCTS IN VARIOUS SPECIES [PDF]
, 1965 Herbert Schumacher +2 more
openalex +1 more source
, 1999 The second in a series re-evaluating hazards identified in the 1950s and ...
Jacobson, Kevin, Mazur, Allan
core +1 more source
Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case
International Medical Case Reports Journal, 2016 Umit Yavuz Malkan, Gursel Gunes, Eylem Eliacik, Ibrahim Celalettin Haznedaroglu Department of Hematology, School of Medicine, Hacettepe University, Ankara, Turkey Abstract: Thalidomide may be used as a treatment option for pyoderma gangrenosum (PG) and ...
Malkan UY +3 more
doaj
Cancer ReportsBackground Thalidomide‐containing regimens cause adverse events (AEs) that may require a reduction in treatment intensity or even treatment discontinuation in patients with multiple myeloma. As thalidomide toxicity is dose‐dependent, identifying the most
Po‐Wei Liao +5 more
doaj +1 more source
Coping with Phantom Risks in the Courts [PDF]
, 1995 Dr. Huber describes phantom risks as those tending to hover indefinitely, never to crystallize.
Huber, Peter W.
core +1 more source
Data in Brief, 2015 Thalidomide is a potent developmental toxicant that induces a range of birth defects, notably severe limb malformations. To unravel the molecular mechanisms underpinning the teratogenic effects of thalidomide, we used microarrays to study transcriptomic ...
Xiugong Gao +2 more
doaj +1 more source
The fate of[14C]thalidomide in the pregnant rabbit [PDF]
, 1967 Sergio Fabro, RL Smith, R. T. Williams
openalex +1 more source
Thalidomide-induced bronchiolitis obliterans organizing pneumonia in a patient with multiple myeloma
Saudi Journal of Kidney Diseases and Transplantation, 2019 Thalidomide, which is an angiogenesis inhibitor and immunomodulator that reduces tumor necrosis factor-alpha, has regained value in the treatment of multiple myeloma. Serious pulmonary complications due to thalidomide use remain relatively uncommon.
Zohra El Ati +11 more
doaj +1 more source
Wellcome Witnesses to Twentieth Century Medicine: Volume 1 [PDF]
, 1998 Annotated and edited transcript of four Witness Seminars. Introduction by E M Tansey First published by the Wellcome Trust, 1997. ©The Trustee of the Wellcome Trust, London, 1997.In Volume One (Occasional Publication no.
Catterall, PP +4 more
core